WO2010104281A3 - 아토피성 피부질환 개선용 조성물 - Google Patents

아토피성 피부질환 개선용 조성물 Download PDF

Info

Publication number
WO2010104281A3
WO2010104281A3 PCT/KR2010/001348 KR2010001348W WO2010104281A3 WO 2010104281 A3 WO2010104281 A3 WO 2010104281A3 KR 2010001348 W KR2010001348 W KR 2010001348W WO 2010104281 A3 WO2010104281 A3 WO 2010104281A3
Authority
WO
WIPO (PCT)
Prior art keywords
skin diseases
composition
atopic skin
improving atopic
present
Prior art date
Application number
PCT/KR2010/001348
Other languages
English (en)
French (fr)
Other versions
WO2010104281A2 (ko
Inventor
최숙영
제훈성
박정규
최재웅
Original Assignee
주식회사 엘지생명과학
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 엘지생명과학 filed Critical 주식회사 엘지생명과학
Publication of WO2010104281A2 publication Critical patent/WO2010104281A2/ko
Publication of WO2010104281A3 publication Critical patent/WO2010104281A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

본 발명은 몬테루카스트 또는 이의 염과 레스베라트롤을 포함하는 조성물을 제공한다. 본 발명에 따른 조성물은 심각한 부작용을 유발하지 않으면서도, 알러지성 질환인 아토피성 피부염(Atopic Dermatitis) 등 아토피성 피부질환의 개선에 매우 우수한 약리 효과를 발휘한다.
PCT/KR2010/001348 2009-03-11 2010-03-04 아토피성 피부질환 개선용 조성물 WO2010104281A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20090020694 2009-03-11
KR10-2009-0020694 2009-03-11

Publications (2)

Publication Number Publication Date
WO2010104281A2 WO2010104281A2 (ko) 2010-09-16
WO2010104281A3 true WO2010104281A3 (ko) 2010-12-23

Family

ID=42728914

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/001348 WO2010104281A2 (ko) 2009-03-11 2010-03-04 아토피성 피부질환 개선용 조성물

Country Status (4)

Country Link
KR (1) KR20100102531A (ko)
AR (1) AR075809A1 (ko)
TW (1) TW201036947A (ko)
WO (1) WO2010104281A2 (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10548837B1 (en) 2016-05-04 2020-02-04 Taro Pharmaceutical Industries Ltd. Topical montelukast for treatment of atopic dermatitis
KR101885120B1 (ko) * 2016-11-11 2018-08-03 전주대학교 산학협력단 옥수수 수염, 들깻잎 및 포도가지 추출물을 유효성분으로 함유하는 항염용 조성물
EP4099982A1 (en) 2020-02-03 2022-12-14 Taro Pharmaceutical Industries Ltd. Topical montelukast formulations
GB2599912B (en) * 2020-10-13 2023-04-19 Diomed Dev Ltd New formulation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008072905A1 (en) * 2006-12-13 2008-06-19 Lg Life Sciences, Ltd. Composition comprising hyaluronic acid and/or its salts for treatment of atopic dermatitis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008072905A1 (en) * 2006-12-13 2008-06-19 Lg Life Sciences, Ltd. Composition comprising hyaluronic acid and/or its salts for treatment of atopic dermatitis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANGELOVA-FISCHER I. ET AL: "Successful treatment of severe atopic dermatities with cysteinyl leukotriene receptor antagonist montelukast", ACTA DERMATOVEN APA, vol. 14, 2005, pages 115 - 119 *
FRIEDMANN P. S. ET AL: "A double-blind, placebo-controlled trial of montelukast in adult atopic eczema", CLINICAL AND EXPERIMENTAL ALLERGY, vol. 37, no. 10, 2007, pages 1536 - 1540 *
RICCIONI, GRAZIANO ET AL: "Advances in therapy with antileukotriene drugs", ANNALS OF CLINICAL & LABORATORY SCIENCE, vol. 34, no. 4, 2004, pages 379 - 387 *

Also Published As

Publication number Publication date
TW201036947A (en) 2010-10-16
KR20100102531A (ko) 2010-09-24
WO2010104281A2 (ko) 2010-09-16
AR075809A1 (es) 2011-04-27

Similar Documents

Publication Publication Date Title
WO2010000877A3 (en) Formulation with irritation reducing action comprising bisabolol and [6]-paradol
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
CL2013001316A1 (es) Composicion que comprende micro-organismo probioticos no replicantes que protegen contra las infecciones del tracto respiratorio superior.
WO2013151665A3 (en) Modified polynucleotides for the production of proteins associated with human disease
BR112013015855A2 (pt) composto, uso de um composto, métodos de prevenção, tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica.
WO2014023640A3 (en) Cosmetic compositions
WO2009126688A8 (en) Novel compositions and methods for the treatment of immune related diseases
WO2012104275A3 (en) Nanoparticles delivery systems, preparation and uses thereof
WO2012095399A3 (en) Personal care compositions
EP2418945A4 (en) Mineral salt-sulfuric acid compositions and methods for their use
WO2013034855A3 (fr) Association de carraghénane et de c-glycoside et leurs utilisations
WO2013174774A3 (en) Cosmetic compositions comprising magnetosomes and uses thereof
WO2012037562A3 (en) Pharmaceutical and nutraceutical compositions of abscisic acid
WO2012049307A3 (en) Novel n-terminally modified insulin derivatives
ZA201101552B (en) Composition comprising chitosan for ocular administration of vaccine(s) to avians
AU2011348474A1 (en) Antimicrobial composition having skin care properties
WO2012053009A3 (en) Pharmaceutical compositions comprising nano size droplets of skin whitening agents
WO2010104281A3 (ko) 아토피성 피부질환 개선용 조성물
WO2011107866A3 (en) Silyl-derivatives of polysaccharides
WO2011014520A3 (en) Compounds and compositions as modulators of gpr119 activity
EP2785335B8 (en) Methods and pharmaceutical compositions for the treatment of darier disease
WO2013038195A3 (en) Pharmaceutical nanoparticle compositions
WO2011046905A3 (en) Pharmaceutical compositions
WO2011156820A9 (en) Compositions, methods and uses for treatment of type 1 diabetes
WO2011127482A3 (en) Modulation of histone deacetylases for the treatment of metabolic disease, methods and compositions related thereto

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10750972

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10750972

Country of ref document: EP

Kind code of ref document: A2